The next generation ofdiagnostic, prognostic, and

therapeutic assessment

Multimethod Analysis of 25+ Hematologic Diseases and Solid Tumors

Anatomic Pathology

MolecularFISH

NeoTYPE™ Cancer Profiles

2 • NeoGenomics Laboratories

NeoTYPE™ Cancer Profiles are multi-method test panels based on next-gen sequencing that identify the genetic changes most significant for

• Confirming diagnosis • Disease classification• Assessing prognosis• Predicting response to therapy• Identifying new therapeutic approaches• Identifying clinical trial opportunities

When to testThese Profiles highlight high-frequency recurrent mutations and provide a practical approach to understanding the cancer’s biology for the most effective patient management. Tests are appropriate for:

• First-line gene testing • Patients with an unusual clinical presentation• Developing therapeutic strategies• Identifying clinical trials• Patients resistant to conventional therapy

NeoGenomics Laboratories • 3

Benefits and Advantages of Targeted Profile Testing• Targeted

Test design is tailored to driver mutations in specific tumors.

• Actionable All genes have clinical significance when mutated.

• ComprehensiveUnique reporting of diagnostic, prognostic, and therapeutic implications.

• FlexibleChoose ‘as-shown’ or as add on.

• EfficientWith fast TAT’s, NeoTYPEs can replace first-line single-gene testing.

• QuantitativeReporting of mutant allele frequencies is useful for monitoring.

• Cost-effective

Flexibility, Performance, Selection Next-generation sequencing (NGS) is widely known for its high sensitivity which aids detection of abnormalities in small biopsies, minimal residual disease, and subclonal heterogeneity. The NeoTYPE next-gen suite offers an additional set of distinct benefits focusing on driver genes and actionable abnormalities, which includes point mutations, indels, translocations, and more.

NeoTYPE Cancer Profiles simplify the laboratory testing process and provide key diagnostic, prognostic, and predictive information you need for up-to-date and fully informed decision-making.

4 • NeoGenomics Laboratories

Sample Report

Sample

NeoGenomics Laboratories • 5

Broad Reach Hematologic ProfilesMyeloid Disorders (54 Molecular)

ABL1 ASXL1 ATRX BCOR BCORL1 BRAF

CALR CBL CBLB CBLC CDKN2A CEBPA

CSF3R CUX1 DNMT3A ETV6 EZH2 FBXW7

FLT3 GATA1 GATA2 GNAS HRAS IDH1

IDH2 IKZF1 JAK2 V617F JAK2 Exon 12+14 JAK3

KDM6A KIT KRAS MLL MPL MYD88

NOTCH1 NPM1 NRAS PDGFRA PHF6 PTEN

PTPN11 RAD21 RUNX1 SETBP1 SF3B1 SMC1A

SMC3 SRSF2 STAG2 TET2 TP53 U2AF1

WT1 ZRSR2

Broad Reach Solid Tumor ProfilesPrecision (48 Molecular, 1 IHC)

ABL1 AKT1 ALK APC ATM

BRAF CDH1 CDKN2A CSF1R CTNNB1

EGFR ERBB2 ERBB4 FBXW7 FGFR1

FGFR2 FGFR3 FLT3 GNA11 GNAQ

GNAS HNF1A HRAS IDH1 JAK2

JAK3 KDR KIT KRAS MET

MLH1 MPL NOTCH1 NPM1 NRAS

PDGFRA PIK3CA PTEN PTPN11 RB1

RET SMAD4 SMARCB1 SMO SRC

STK11 TP53 VHL PD-L1 IHC

Discovery (315 Molecular, 9 FISH, 1 IHC)Next-gen sequencing of 315 genes + 9 FISH + PD-L1 IHC. This is an actionable discovery panel suitable for clinical research applications and wide-spectrum patient testing. See website or handout for complete test details.

Cancer Exome (4813 Molecular)Next-gen sequencing of 4813 cancer-related genes. Testing is recommended for those interested in academic or clinical research. See website for complete test details, or call our Client Services Team at 866.776.5907.

Cancer-Specific Hematologic ProfilesAITL/Peripheral T-Cell Lymphoma Profile (5 Molecular)

DNMT3A IDH1 IDH2 RHOA TET2

AML Favorable-Risk (2 Molecular)

FLT3 KIT

AML Prognostic (27 Molecular)

ASXL1 BCOR BRAF

CEBPA CSF3RDNMT3A

ETV6EZH2 FLT3

HRAS IDH1IDH2

JAK2 KIT KRAS

MLL NPM1 NRAS

PDGFRA PHF6 PTPN11

RUNX1SETBP1STAG2

TET2TP53WT1

CLL Prognostic (5 Molecular, 1 FISH Panel)

IgVH Mutation MYD88 NOTCH1 SF3B1 TP53 CLL FISH Panel

JMML (16 Molecular)BRAF CBL

CEBPA FLT3

HRAS JAK2 V617F

JAK2 Exon 12+14JAK3

KIT KRAS

NPM1 NRAS

PDGFRA PTEN

PTPN11SETBP1

Lymphoma (8 Molecular)

BCL1 BCL2 BRAF CARD11 CD79B EZH2 MYD88 NRAS

MDS/CMML (32 Molecular)

ASXL1 BCORBCORL1

BRAFCBLCEBPA

CUX1DNMT3AETV6

EZH2 FLT3 HRAS

IDH1 IDH2 JAK2 V617F

JAK2 Exon 12+14 KIT

KRAS NPM1 NRAS

PDGFRA PTEN PTPN11

RUNX1SETBP1SF3B1

SRSF2 STAG2 TET2

TP53 U2AF1ZRSR2

MPN (25 Molecular)

ABL1 ASXL1BRAF

CALR CEBPA CSF3R

EZH2 FLT3 HRAS

IDH1IDH2JAK2 V617F

JAK2 Exon 12+14 KIT KRAS

MPL NPM1 NRAS

PDGFRA PTEN PTPN11

SETBP1SRSF2 TET2

U2AF1

NeoGenomics Laboratories • 6

Cancer-Specific Solid Tumor ProfilesBrain (22 Molecular, 5 FISH, 1 IHC)

AKT1ATRXBRAFCTNNB1

EGFREGFRvlll Analysis ERBB2

ERBB4FGFR1FGFR2FGFR3

IDH1 IDH2 MET

MGMT PromoterMethylation PIK3CA

PTENSMAD4SMOSRC

TERT Promoter TP531p/19q Deletion FISH

BRAF FISHMET FISHMYCN FISHPTEN FISH

PD-L1 IHC

Breast (22 Molecular, 3 FISH, 1 IHC)AKT1BRAFBRCA1

BRCA2CTNNB1EGFR

ERBB2ERBB4 FGFR1

FGFR2FGFR3HRAS

KIT KRASMET

NRASPIK3CAPTEN

SMAD4SMOSRC

TP53HER2 FISH MET FISH

PTEN FISHPD-L1 IHC

Cervical (22 Molecular, 2 FISH, 1 IHC)AKT1BRAFCTNNB1

EGFRERBB2ERBB4

FGFR1FGFR2FGFR3

HRASJAK3KRAS

METNOTCH1NRAS

PDGFRAPIK3CAPTEN

SMAD4 SMO SRC

TP53MET FISHPTEN FISH

PD-L1 IHC

Colorectal (24 Molecular, 2 FISH, 1 IHC)

AKT1APC BRAFEGFR

ERBB2 ERBB4FGFR1FGFR2

FGFR3 HRAS JAK3 KIT

KRAS MET Microsatellite Instability (MSI)

MLH1 Promoter MethylationNOTCH1NRASPDGFRA

PIK3CAPTENSMO SRC

TP53 MET FISHPTEN FISHPD-L1 IHC

Endometrial (21 Molecular, 2 FISH, 1 IHC)

AKT1BRAFEGFR

FGFR1FGFR2FGFR3

HRAS JAK3 KIT

KRAS METMicrosatellite Instability (MSI)

NRASPDGFRAPIK3CA

PTENPTPN11SMAD4

SMOSRC TP53

MET FISHPTEN FISHPD-L1 IHC

Esophageal (22 Molecular, 3 FISH, 1 IHC)

AKT1BRAFCTNNB1ERBB2

ERBB4FGFR1FGFR2FGFR3

HRASJAK3 KITKRAS

METNOTCH1NRASPDGFRA

PIK3CAPTENSMAD4SMO

SRC TP53HER2 FISHMET FISH

PTEN FISHPD-L1 IHC

Gastric (22 Molecular, 3 FISH, 1 IHC)

AKT1BRAFEGFR

ERBB2ERBB4FGFR1

FGFR2FGFR3HRAS

JAK3 KITKRAS

METNOTCH1NRAS

PDGFRAPIK3CAPTEN

SMAD4SMOSRC

TP53HER2 FISHMET FISH

PTEN FISH PD-L1 IHC

GIST (11 Molecular, 1 IHC)AKT1BRAF

CTNNB1ERBB2

ERBB4FGFR1

FGFR2FGFR3

KITPDGFRA

SRCPD-L1 IHC

Head & Neck (25 Molecular, 2 FISH, 1 IHC)

AKT1ATMBRAF

CDKN2ACTNNB1EGFR

ERBB2 ERBB4FGFR1

FGFR2FGFR3HRAS

IDH1IDH2 KRAS

METNOTCH1NRAS

PIK3CAPTENRB

SMOSRC TP53

MET FISHPTEN FISHPD-L1 IHC

HPV DNA Tissue Test

Liver/Biliary (24 Molecular, 2 FISH, 1 IHC)

AKT1ATMBRAF

CDKN2ACTNNB1EGFR

ERBB2ERBB4FGFR1

FGFR2FGFR3 HRAS

IDH1IDH2KRAS

METNOTCH1NRAS

PIK3CAPTENSMAD4

SMOSRCTP53

MET FISHPTEN FISHPD-L1 IHC

Liposarcoma Fusion Profile (5 Molecular, 1 FISH)

COL1A2-PLAG1 EWSR1-DDIT3 FUS-DDIT3 HMGA2-LPP LPP-HMGA2 MDM2 FISH

Lung (21 Molecular, 6 FISH, 1 IHC)

AKT1BRAF EGFR

ERBB2ERBB4FGFR1

FGFR2FGFR3 KIT

KRASMET

MET Exon 14 Deletion AnalysisNOTCH1

NRASPDGFRAPIK3CA

PTEN SMAD4 SMO

SRC TP53 ALK FISH

HER2 FISHMET FISHPTEN FISH

RET FISHROS1 FISH PD-L1 IHC

Melanoma (17 Molecular, 1 FISH, 1 IHC)

AKT1BRAF

CTNNB1EGFR

ERBB2ERBB4

FGFR1 FGFR2

FGFR3GNAQ

KITNRAS

PDGFRAPTEN

SMO SRC

TERT Promoter

PTEN FISHPD-L1 IHC

Other Solid Tumor (24 Molecular, 2 FISH, 1 IHC)AKT1 BRAF EGFR

FGFR1FGFR2FGFR3

GNASHRASIDH1

IDH2 JAK3KIT

KRASMETNOTCH1

NRASPDGFRAPIK3CA

PTEN PTPN11SMAD4

SMO SRC TP53

MET FISHPTEN FISHPD-L1 IHC

Ovarian (22 Molecular, 2 FISH, 1 IHC)AKT1BRAF BRCA1

BRCA2CTNNB1EGFR

ERBB2 ERBB4 FGFR1

FGFR2FGFR3 HRAS

JAK3 KRAS MET

NRASPIK3CAPTEN

SMAD4 SMOSRC

TP53 MET FISHPTEN FISH

PD-L1 IHC

Pancreas (22 Molecular, 3 FISH, 1 IHC)AKT1 BRAF BRCA1

BRCA2 EGFR ERBB2

ERBB4 FGFR1FGFR2

FGFR3 HRAS KIT

KRASMETNOTCH1

NRASPDGFRAPIK3CA

PTENSMOSRC

TP53HER2 FISHMET FISH

PTEN FISHPD-L1 IHC

Soft Tissue (19 Molecular, 2 FISH, 1 IHC)

AKT1 BRAF FGFR1

FGFR2 FGFR3GNAS

HRAS JAK3KIT

KRASMETNRAS

PDGFRAPIK3CA PTEN

SMAD4SMOSRC

TP53MET FISHPTEN FISH

PD-L1 IHC

Thyroid (16 Molecular, 2 FISH, 1 IHC)

AKT1 ALK

BRAFCTNNB1

ERBB2ERBB4

HRAS KRAS

METNRAS

PIK3CARET

SMAD4SMO

SRC TERT Promoter

MET FISHRET FISH

PD-L1 IHC

Options for CustomizationAdd-OnsAny genes in the 54-gene Myeloid Disorders Profile may be added to any of the Hematologic Diseases Profiles.Any genes in the 48-gene Precision Profile for Solid Tumors may be added to any of the other Solid Tumor Profiles.Results of testing for added genes will be included in the comprehensive NeoTYPE report for that Profile.

Tech-Only FISHThis option is available to pathology clients who want to perform the professional components of any FISH tests within a Profile. These clients should order the component FISH tests as tech-only in combination with the molecular portion of the Profile.

NeoGenomics Laboratories • 7

12701 Commonwealth Dr., Suite 9Fort Myers, FL 33913 Phone: 866.776.5907/ Fax: 239.690.4237 neogenomics.com© 2017 NeoGenomics Laboratories, Inc. All Rights Reserved.All other trademarks are the property of their respective owners.Rev. 030117

Ordering InformationSpecimen options:• Peripheral blood• Bone marrow aspirate• Fresh tissue• FFPE slides or block

TAT: 10-22 days (varies by Profile)

Billing: NeoGenomics offers institutional and third-party billing.

New tests are in development. Sign up at www.neogenomics.com to be notified.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-approved laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publication with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.